Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
224
resultados
Última actualización
26/07/2025 [06:53:00]
Resumen de: CN120361008A
本发明提供了基于米尔贝肟吡喹酮的寄生虫驱除药物，以质量份计，所述药物包括以下组分：改性米尔贝肟10‑30份、纳米包覆吡喹酮20‑50份、复配增效剂5‑15份、矫味剂3‑8份、崩解剂2‑5份。基于米尔贝肟吡喹酮的寄生虫驱除药物的应用，所述药物用于制备预防或治疗犬、猫的混合寄生虫感染的制剂，所述寄生虫包括绦虫、线虫、吸虫及蠕形螨。本申请通过化学改性（琥珀酰化米尔贝肟）、纳米技术（HPMC包覆吡喹酮）、复配协同（非班太尔‑β环糊精）的集成创新，实现广谱驱虫、长效稳定、安全低毒的综合优势，同时解决现有技术中适口性差、代谢负担高、环境适应性弱等痛点，适用于犬猫混合寄生虫感染的预防与治疗。
Resumen de: CN120364654A
本申请提供了一种红色纳米硒颗粒的制备方法及其应用，涉及纳米医药技术领域，制备方法包括将亚硒酸钠溶于超纯水，加入含铜锌铝硅酸盐微球，pH至4.8，搅拌滴加1.5M抗坏血酸溶液，升温至加入固体抗坏血酸，用NaOH调节pH，搅拌反应得到纳米硒悬浮液；将纳米硒悬浮液、海藻酸钠巯基氧化石墨烯混合物和壳寡糖柠檬酸缓冲液混合搅拌，离心洗涤后冷冻干燥，得到红色纳米硒颗粒，所述含铜锌铝硅酸盐微球通过介孔模板煅烧及铜锌共掺杂制备，用该方法制备出的红色纳米硒颗粒具有核壳结构，粒径均一且抗氧化性强的同时具有显著的界面结合强度。
Resumen de: US2024245618A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: WO2024177578A1
A method of producing a biomolecule-crosslinked compound is disclosed. More specifically, the method comprises the steps of reacting a plurality of monomers and a plurality of comonomers in the presence of ammonia within a first solution to generate a compound; retrieving the produced compound from the first solution for cleaning; subjecting the cleaned compound to react with a second solution to join a crosslinker onto the compound through a first amine functional group of the crosslinker; and adding a plurality of biomolecules to the second solution to bind the biomolecules towards the compound through a second amine functional group of the crosslinker to produce the biomolecule-crosslinked compound.
Resumen de: CN120361241A
本发明涉及一种白蛋白功能化硫化钽纳米点在制备治疗急性肾损伤药物中的应用，属于纳米药物新用途技术领域。本发明所用的白蛋白功能化硫化钽纳米点由安全无毒且无免疫原性的理想载体白蛋白和高生物相容的层状过渡金属硫化钽简单高效组装而成；能够凭借其超小粒径穿越肾小球滤过屏障特异性蓄积于肾脏，利用白蛋白与巨蛋白受体的特异性结合主动内化至近端小管上皮细胞，又依赖白蛋白对线粒体的高亲和力序贯定位至线粒体。该纳米点在急性肾损伤病理损伤微环境中通过钽离子活跃的价态变化高效清除活性氧并保护线粒体，限制细胞凋亡、免疫激活及无菌性炎症，进而实现近端小管上皮细胞损伤缓解并有效恢复肾脏功能。
Resumen de: AU2023408183A1
Aspects of the disclosure relate to compositions and methods for improving the stability of lipid nanoparticles (LNPs). In some embodiments, the LNPs comprise one or more active pharmaceutical ingredients (API) encapsulated therein. The disclosure is based, in part, on compositions that directly or indirectly reduce the degradation (e.g., oxidation, hydrolysis, etc.) of one or more lipids components of the lipid nanoparticle. In some embodiments, the compositions comprise a histidine buffer. The disclosure also provides methods for storing compositions contemplated herein as well as methods for improving the stability of the API.
Resumen de: CN120361244A
本发明公开了一种电诱导辅助制备的营养递送体系及其制备方法和应用，制备方法为：将两亲性成壳蛋白和脂溶性的包埋物分别溶于溶剂A中，得到包埋物/两亲性成壳蛋白溶液，将其滴加到溶剂B或壳聚糖的C溶液中，所述壳聚糖溶液由壳聚糖溶解到溶剂C中得到，在滴加过程中通入40V，100mA的持续电流，包埋物/两亲性成壳蛋白在溶剂A或溶剂C中析出，负压蒸发，调节pH值，得到电诱导辅助制备的载包埋物的两亲性成壳蛋白基纳米颗粒或两亲性成壳蛋白基‑壳聚糖纳米颗粒，两者均为核壳结构，包埋物为核，两亲性成壳蛋白或被壳聚糖修饰的两亲性成壳蛋白为壳。本发明采用电诱导法辅助制备营养递送体系具有简便高效，反应条件温和，无毒副作用等特点。
Resumen de: CN120360968A
本申请提供一种麦角甾醇纳米分散体及其制备方法和应用，麦角甾醇纳米分散体包括麦角甾醇芯材和包裹所述麦角甾醇芯材至少部分表面的大豆分离蛋白壁材，所述分散体的粒径为250‑400 nm，所述分散体的PDI为0.034‑0.106。该分散体特殊的组成及相关参数，显著改善了麦角甾醇在水中的分散性、均一性和生物可及性。
Resumen de: CN120361109A
本发明涉及一种去腐生肌抗感染药膏及其制备方法，属于中药技术领域。本发明以地榆、黄连、黄柏、黄芩、虎杖、紫草、冰片、蜂蜡、香油为基础原料制备去腐生肌抗感染药膏；将地榆提取物制成pH响应纳米粒和紫草提取物制成紫草提取物‑硫辛酸复合物靶向坏死组织释放活性物质，促进坏死组织的自然去除，同时保护健康组织。
Resumen de: CN120360969A
本发明公开了双靶向巨噬细胞膜纳米系统及其制备方法与应用，属于生物医药领域，MKA由AuNPs与线粒体靶向肽KLA连接后包裹于巨噬细胞膜内。制备时先合成AuNPs并修饰，再用巨噬细胞膜包裹。在治疗中，它能双靶向肿瘤细胞和线粒体，增强辐射诱导的DNA损伤，抑制DDR，激活免疫通路，促进T细胞浸润，还可消耗谷胱甘肽、放大氧化应激来增强免疫效果，与8GyX射线协同的剂量增强比达3.1。此外，MKA在体内生物相容性良好，血液循环时间长、肿瘤靶向性高且能快速经肾脏清除。该发明为肿瘤放射免疫治疗提供新途径，有助于推动临床肿瘤治疗的进步。
Resumen de: CN120360965A
本发明公开了一种基于多酚氧化偶联自组装的pH响应性口服纳米药物及其制备方法和应用。该纳米药物设计简单高效，本发明所述的纳米药物是基于多酚在酸性介质中通过氧化剂介导的氧化偶联自组装，提供了一种耐酸不耐碱的pH响应性口服递送载体。通过溶剂转换介导的解组装‑重组装作用，高效负载疏水性药物，制备得到口服纳米药物。本纳米策略极大的提高了疏水性药物的载药率，载药量高达50％。同时避免了纳米药物被恶劣的胃生理环境破坏，靶向肠道递送。基于生物活性的多酚载体与药物之间的双重抗炎抗氧化作用，该口服纳米药物能够作为优异的多功能药物制剂通过协同作用预防或治疗炎症性肠病。
Resumen de: CN120360189A
本发明公开了一种幼鹅养殖饲料，属于养殖饲料技术领域，来解决现有改进型饲料仍存在配方复杂、成本高、效果不稳定的问题，能量原料占55‑68%，优选62%；蛋白原料占22‑30%，优选26%；预混料占5‑8%，优选6.5%；功能添加剂占3‑7%，优选5.5%，通过复合酶制剂与微生态制剂的协同作用，显著提高了粗蛋白消化率，使其提升至78.6%（P＜0.01），有效提高了饲料的利用效率，利用纳米包被技术形成的缓释体系，使维生素D3半衰期延长至48小时，持续为幼鹅提供稳定的维生素D3来源，促进钙、磷吸收和骨骼发育，根据幼鹅不同生长阶段对钙、磷的需求，将钙磷比在1.8:1‑2.2:1进行梯度调整，满足幼鹅骨骼发育和新陈代谢的需求，减少因钙磷失衡导致的疾病。
Resumen de: CN120361235A
本发明提供了一种双靶向类载体材料、制备方法、及其包裹的齐墩果酸纳米粒的制备方法，属于医药技术领域。以双靶向性的高分子共聚物为载体材料，采用乳化‑溶剂挥发法制备齐墩果酸靶向纳米粒，能够保护齐墩果酸不被快速降解，延长其在体内的循环时间。同时，通过靶向基团，实现对齐墩果酸的靶向递送，提高药物在肿瘤组织的浓度，降低对正常组织的毒副作用。采用MTT法，研究齐墩果酸纳米粒对细胞生长的抑制作用，结果显示，齐墩果酸靶向纳米粒具有相对于齐墩果酸原料药具有更强的抑制肿瘤细胞增殖的作用。
Resumen de: WO2025153097A1
The use of blank lipid nanoparticles in the preparation of an in-vivo delivery product, comprising the step of mixing the blank lipid nanoparticles with a biologically active substance in a solvent to obtain a blank lipid nanoparticle-based composition. The blank lipid nanoparticles consist of an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-lipid conjugate. According to the blank lipid nanoparticles, the dosage of the biologically active substance can be flexibly adjusted according to the requirements of a user, and the blank lipid nanoparticles can be administered via multiple routes such as intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, all of which can achieve an ideal delivery effect.
Resumen de: US2025235524A1
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of ribonucleic acid immunogenic compositions and/or vaccines comprising polynucleotide molecules preferably encoding one or more influenza antigens, such as hemagglutinin antigens, wherein the composition is frozen or lyophilized.
Resumen de: WO2025152109A1
A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.
Resumen de: US2025236585A1
The present invention provides an ionizable lipid compound, which can target spleen for delivery of biological macromolecules including nucleic acid drugs or nucleic acid vaccines with high efficiency. The present invention also relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and an active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Resumen de: US2025236645A1
This present disclosure provides RNA expression systems based on sequences from plant viruses, insect viruses, and flaviviruses that eliminate the need for expensive modifications. Methods to express and package an RNA polynucleotide without the need for in vitro transcription and lipid nanoparticles are provided. Also provided are methods to package an RNA polynucleotide using synthetic polyanhydride nanoparticles that are stable at room temperature and suitable for delivery by nasal spray.
Resumen de: US2025236599A1
The current invention relates to ionizable lipid-like compound according to Formula (I) or pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.The present invention also provides a lipid nanoparticle comprising an ionizable lipid-like compound according to Formula I and one or more RNA molecules, as well as a pharmaceutical composition or vaccine, comprising such lipid nanoparticles.
Resumen de: US2025235500A1
Disclosed in the present invention are a new polypeptide for promoting tissue repair, and the use thereof. The new polypeptide can promote the proliferation of human immortalized epidermal cells and the migration of human epidermal fibroblasts at a relatively low concentration, can promote the repair of wounds and ulcers, improves the aesthetic feeling of the skin, has low toxic side effects, has good application prospects, and can be used for preparing a drug and a medical instrument for treating wound surfaces, scalds and ulcers or for preparing an everyday chemical for improving the aesthetic feeling of the skin.
Resumen de: US2025235411A1
The present disclosure provides lipid nanoparticle compositions and methods of use. Among other things the present disclosure provides lipid nanoparticle compositions which increased specificity for specific cells or tissues. The present disclosure provides methods of use of the disclosed lipid nanoparticles.
Resumen de: US2025235412A1
A poly(beta-aminoester) polymer of formula (I) or a pharmaceutically salt thereof which comprises one or more zwitterionic polymers. Advantageously, the polymer of the invention shows improved properties when formulated in the form of nanoparticles. Processes for the preparation of the polymer, nanoparticles comprising a polymer of Formula (I) and uses thereof.
Resumen de: US2025235404A1
Disclosed herein are polyethylene glycol (PEG)-lipids, functionalized PEG-lipids, and functionalized PEG-lipids that are conjugated to a binding moiety which can comprise an antibody antigen binding domain. Also disclosed are methods for synthesizing and functionalizing the PEG-lipids. The PEG-lipids are useful components lipid nanoparticles (LNP) used for the delivery of nucleic acids into living cells, in vivo or ex vivo. LNP comprising functionalized PEG-lipids that are conjugated to a binding moiety are useful as targeted LNP for delivering nucleic acids into cells or tissues expressing the ligand of the binding moiety.
Resumen de: US2025235394A1
Nanoparticles for treating a tooth in an oral cavity of a subject are provided. The nanoparticle comprises a biocompatible and biodegradable hydrophilic polymer, a matrix-degrading enzyme, and an anticaries active ingredient present in the nanoparticle at greater than or equal to about 20% by weight. The nanoparticle has a zeta potential between about −10 mV to about +10 mV at a pH of 7. The nanoparticle is capable of selectively accumulating within a biofilm matrix associated with a surface of the tooth in the oral cavity of the subject. Oral care composition and methods of treating a tooth in an oral cavity of a subject with such nanoparticles are also provided.
Nº publicación: US2025235405A1 24/07/2025
Solicitante:
BRANCA BUNUS LTD [IE]
BRANCA BUNUS LIMITED
Resumen de: US2025235405A1
A nanoparticulate composition comprising a core comprising a therapeutically active agent selected from a nucleic acid, protein or peptide packaged within a non-viral drug delivery vehicle is described. The core comprises a low molecular weight stabilizing agent comprising at least one atom or group that is charged in aqueous solution, wherein when the therapeutic agent is negatively charged the charged atom or group is positively charged in aqueous solution and when the therapeutic agent is positively charged the charged atom or group is negatively charged in aqueous solution.
BOPI
Sede Electrónica
